Skip to main content

rintatolimod

rintatolimod: 6 clinical trials tracked.

rintatolimod evidence translation

What we can confirm

6 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about rintatolimod, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 2 study sponsors
Clinical Trials (6)

A Phase 2 Randomized Open-Label Controlled Study to Evaluate the Efficacy and Safety of Ampligen in Combination With Standard of Care Versus SOC Alone Following First-Line Therapy in Subjects With Locally Advanced Pancreatic Adenocarcinoma

NCT05494697·Phase 2·AIM
Suspended

Primary endpoint: Progression Free Survival (PFS)

InterventionalRandomizedopen90 targetStarted 2027-08Completion 2031-033 sites · United StatesAIM ImmunoTech Inc.

A Phase 2 Efficacy Trial of Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer

NCT07634094·Phase 2
Not yet recruiting

Primary endpoint: Dose Limiting Toxicities (DLT)

Interventionalopen28 targetStarted 2026-08Completion 2029-081 site · United StatesKalinski, Pawel, MD, PhD

A Phase II Study of Type-1 Polarized Dendritic Cell (aDC1) -Based Treatment in Combination With Tumor-Selective Chemokine Modulation (CKM: Interferon Alpha 2b, Rintatolimod and Celecoxib) in Melanoma Patients With Primary PD-1/PD-L1 Resistance

NCT04093323·Phase 2·AIM
Terminated

Primary endpoint: Objective Response Rate (ORR)

Interventionalopen1 targetStarted 2024-11Completion 2025-061 site · United StatesRoswell Park Cancer Institute

Phase 1/2A Study of Rintatolimod and IFN Alpha Regimen in Cancer Patients With COVID-19

NCT04379518·Phase 1/Phase 2·PARK
Terminated

Primary endpoint: Number of Participants With Adverse Events (AEs)

Interventionalopen4 targetStarted 2020-11Completion 2023-031 site · United StatesRoswell Park Cancer Institute

Randomized Phase 2 Study: Neoadjuvant Conditioning of Prostate Cancer Tumor Microenvironment Using a Novel Chemokine-Modulating Regimen

NCT03899987·Phase 2·PARK
Active, not recruiting

Primary endpoint: Count of tumor infiltrating CD8+ lymphocytes

InterventionalRandomizedopen12 targetStarted 2019-11Completion 2027-041 site · United StatesRoswell Park Cancer Institute

Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer

NCT03734692·Phase 1/Phase 2
Active, not recruiting

Primary endpoint: Objective Response Rate (ORR)

Interventionalopen24 targetStarted 2019-01Completion 2027-011 site · United StatesRobert Edwards